Study wrapper · #1096
Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use.
Peng DS, Shen A, Smart C, et al. JAAD case reports. 2026.
DOI: 10.1016/j.jdcr.2026.06.006PubMed: 42541308
Editor's note
A single case report of a skin eruption associated with tirzepatide offers a safety signal worth noting but carries limited evidentiary weight. It documents a possible adverse reaction rather than establishing incidence or causality.
Plain-language abstract
This single case report describes a morbilliform (measles-like) skin rash associated with tirzepatide, noting the relevance of such reactions as GLP-1 agonist use rises. A single case cannot establish how often this occurs.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026